Phase II study of intraperitoneal paclitaxel combined with S-1 plus cisplatin for advanced gastric cancer with peritoneal metastasis

Phase 2

• Conditions: Gastric cancer; Gastric cancer, peritoneal metastasis

• Registration Number: JPRN-jRCTs041180079
• Lead Sponsor: Kodera Yasuhiro

Brief Summary

S-1/cisplatin plus intraperitoneal paclitaxel for gastric cancer with peritoneal dissemination was suggested to be safe and effective.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-03-11
• Study Completion: 2021-07-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 53

Inclusion Criteria

1) Histologically proven unresectable or recurrent gastric adenocarcinoma
2) Peritoneal metastasis
3) No prior chemotherapy
4) Adequate bone marrow function
5) Eastern Cooperative Oncology Group performance status 0-1
6) An expected survival period of more than 3 months
7) Written informed consent.

Exclusion Criteria

1) Metastasis to distant organ sites (such as the liver, lungs or bone)
2) Other active concomitant malignancies
3) other severe medical conditions; pregnant
4) unwilling to practice contraception during the study, or lactating female

Study & Design

• Study Type: Interventional
• Study Design: Not specified